Predictive performance of population pharmacokinetic models of imatinib in chronic myeloid leukemia patients.

ABSTRACT:

Background and aim

Chronic myeloid leukemia is a myeloproliferative neoplasm associated with the specific chromosomal translocation known as the Philadelphia chromosome. Imatinib is a potent BCR-ABL tyrosine kinase inhibitor, which is approved as the first line therapy for CML patients. There are various population pharmacokinetic studies available in the literature for this population. However, their use in other populations outside of their cohort for the model development has not been evaluated. This study was aimed to perform the predictive performance of the published population pharmacokinetic models for imatinib in CML population and propose a dosing nomogram.

Methods

A systematic review was conducted through PubMed, and WoS databases to identify PopPK models. Clinica

SUBMITTER: Dilli Batcha JS 

PROVIDER: S-EPMC11258086 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature